Skip to main content
TipRanks
Go Ultimate75% OFF

Arrowhead Pharmaceuticals (ARWR) Stock Price & Analysis

1,737 Followers

ARWR Stock Chart & Stats

$41.37-$2.28(-5.22%)
At close: 4:00 PM EST
$40$60$80Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$41.17 - $44.80
52-Week Range
$37.43 - $95.49
Previous Close
$43.65
Volume
N/A
Average Volume (3M)
2.17M
Market Cap
$5.85B
Enterprise Value
$9.46B
Total Cash (Recent Filing)
$1.19B
Total Debt (Recent Filing)
$1.00B
Price to Earnings (P/E)
―
Beta
2.17
Next Earnings
Feb 10, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

REDEMPLO Commercial Traction

Rapid prescription and prescriber growth provides early evidence of demand for REDEMPLO and supports the commercial platform being built around the product. Continued adoption could create a more durable revenue base as payer access expands and physicians gain experience.

Strong Plozasiran Efficacy

Consistent pivotal efficacy across two studies strengthens the case for plozasiran as a differentiated treatment in severe hypertriglyceridemia. The depth of lipid reduction and broad endpoint success could support regulatory approval, physician adoption, and long-term commercial relevance.

Improved Debt Structure

Refinancing materially lowers the stated interest rate versus the retired facility and extends maturity without scheduled amortization. These terms can preserve cash for clinical development and commercialization while reducing near-term repayment pressure, despite continued leverage.

Bears Say

Severe Profitability Deterioration

The sharp move to a large loss shows that operating costs currently overwhelm commercial and licensing revenue. Unless product revenue scales substantially or spending moderates, persistent losses can consume capital, reduce financial flexibility, and delay the path toward sustainable profitability.

Elevated Leverage And Financial Risk

The combination of high debt and a sharply reduced equity base leaves Arrowhead less able to absorb development setbacks or prolonged losses. Elevated leverage can increase refinancing and dilution risk and may constrain capital allocation as the company funds a costly pipeline.

Uncertain SHTG Launch Execution

The expected sHTG launch is not yet assured because approval, labeling, payer interaction, and commercial assumptions remain unresolved. Any delay or restrictive label could postpone meaningful revenue, complicate planning, and leave the company dependent on financing while expenses remain elevated.

Arrowhead Pharmaceuticals News

ARWR FAQ

What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $37.43 and its highest was $95.49 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $5.85B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s next earnings report is estimated for Feb 10, 2027 (not yet confirmed), which is in 80 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Nov 12, 2026. The company reported -$3.04 earnings per share for the quarter, missing the consensus estimate of -$1.518 by -$1.522.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -1.45.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 141,368,010 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$3.04 in its last earnings report, missing expectations of -$1.518. Following the earnings report the stock price went up 1.336%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Hedge funds hold Arrowhead Pharmaceuticals shares: the largest hedge-fund position in Arrowhead Pharmaceuticals is 72,324,409 shares, and hedge funds decreased their holdings by 1.1M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology